Medicare Program; Membership and Meeting Announcement for the Advisory Panel on Clinical Diagnostic Laboratory Tests, 13756-13758 [2018-06556]
Download as PDF
<![CDATA[
13756
Federal Register / Vol. 83, No. 62 / Friday, March 30, 2018 / Notices
amozie on DSK30RV082PROD with NOTICES
determination. However, we may
request missing information following
the meeting to prevent a
recommendation from being considered
incomplete.
Taking into account the comments
and recommendations (and
accompanying data) received at the
Annual Laboratory Public Meeting, we
intend to post our proposed
determinations with respect to the
appropriate basis for establishing a
payment amount for each new test code
and our preliminary determinations
with respect to the reconsidered codes
along with an explanation of the reasons
for each determination, the data on
which the determinations are based, and
a request for public written comments
on these determinations on the CMS
website by early September 2018. This
website can be accessed at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
ClinicalLabFeeSched/
index.html?redirect=/
ClinicalLabFeeSched/. Interested parties
may submit written comments on the
preliminary determinations for new and
reconsidered codes by early October
2018, to the address specified in the
ADDRESSES section of this notice or
electronically to our CLFS dedicated
email box, CLFS_Annual_Public_
Meeting@cms.hhs.gov (the specific date
for the publication of the determinations
on the CMS website, as well as the
deadline for submitting comments
regarding the determinations, will be
published on the CMS website). Final
determinations for new test codes to be
included for payment on the CLFS for
CY 2019 and reconsidered codes will be
posted on the CMS website in
November 2018, along with the
rationale for each determination, the
data on which the determinations are
based, and responses to comments and
suggestions received from the public.
The final determinations with respect to
reconsidered codes are not subject to
further reconsideration. With respect to
the final determinations for new test
codes, the public may request
reconsideration of the basis and amount
of payment as set forth in § 414.509.
III. Registration Instructions
The Division of Ambulatory Services
in the CMS Center for Medicare is
coordinating the CLFS public meeting
registration. Beginning April 4, 2018,
and ending June 11, 2017, registration
may be completed on-line at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
ClinicalLabFeeSched/
index.html?redirect=/
ClinicalLabFeeSched/. On this web
VerDate Sep<11>2014
18:57 Mar 29, 2018
Jkt 244001
page, under the heading ‘‘Meeting
Notice, Registration and Agenda,’’ you
will find a link entitled ‘‘Register for
CLFS Annual Meeting’’. Click this link
and enter the required information. All
the following information must be
submitted when registering:
• Name.
• Company name.
• Address.
• Telephone numbers.
• Email addresses.
When registering, individuals who
want to make a presentation must also
specify the new test codes on which
they will be presenting comments. A
confirmation will be sent upon receipt
of the registration. Individuals must
register by the date specified in the
DATES section of this notice.
If not attending the Annual
Laboratory Public Meeting in person,
the public may view the meeting via
webcast or listen by teleconference.
During the public meeting, webcasting
is accessible online at https://cms.gov/
live. Teleconference dial-in information
will appear on the final Annual
Laboratory Public Meeting agenda,
which will be posted on the CMS
website when available at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/
ClinicalLabFeeSched/
index.html?redirect=/
ClinicalLabFeeSched/.
instructions will be issued after the
vehicle inspection.
• Passing through a metal detector
and inspection of items brought into the
building. We note that all items brought
to CMS, whether personal or for the
purpose of demonstration or to support
a demonstration, are subject to
inspection. We cannot assume
responsibility for coordinating the
receipt, transfer, transport, storage, setup, safety, or timely arrival of any
personal belongings or items used for
demonstration or to support a
demonstration.
IV. Security, Building, and Parking
Guidelines
Dated: March 20, 2018.
Seema Verma,
Administrator, Centers for Medicare &
Medicaid Services.
The meeting will be held in a Federal
government building; therefore, Federal
security measures are applicable. In
planning your arrival time, we
recommend allowing additional time to
clear security. We suggest that you
arrive at the CMS facility between 7:00
a.m. and 8:00 a.m. E.D.T., so that you
will be able to arrive promptly at the
meeting by 8:00 a.m. E.D.T. Individuals
who are not registered in advance will
not be permitted to enter the building
and will be unable to attend the
meeting. The public may not enter the
building earlier than 7:15 a.m. E.D.T.
(45 minutes before the convening of the
meeting).
Security measures include the
following:
• Presentation of government-issued
photographic identification to the
Federal Protective Service or Guard
Service personnel. Persons without
proper identification may be denied
access to the building.
• Interior and exterior inspection of
vehicles (this includes engine and trunk
inspection) at the entrance to the
grounds. Parking permits and
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
V. Special Accommodations
Individuals attending the meeting
who are hearing or visually impaired
and have special requirements, or a
condition that requires special
assistance, should provide that
information upon registering for the
meeting. The deadline for registration is
listed in the DATES section of this notice.
VI. Collection of Information
Requirements
This document does not impose
information collection requirements,
that is, reporting, recordkeeping or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
[FR Doc. 2018–06551 Filed 3–29–18; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–1706–N]
Medicare Program; Membership and
Meeting Announcement for the
Advisory Panel on Clinical Diagnostic
Laboratory Tests
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice announces the
appointment of three new members to
the Medicare Advisory Panel on Clinical
Diagnostic Laboratory Tests (the Panel)
and the next public meeting for the
Panel, which is scheduled on Monday,
July 16, 2018 and Tuesday, July 17,
2018.
SUMMARY:
E:\FR\FM\30MRN1.SGM
30MRN1
amozie on DSK30RV082PROD with NOTICES
Federal Register / Vol. 83, No. 62 / Friday, March 30, 2018 / Notices
The purpose of the Panel is to advise
the Secretary of the Department of
Health and Human Services and the
Administrator of the Centers for
Medicare & Medicaid Services on issues
related to clinical diagnostic laboratory
tests.
DATES:
Meeting Dates: The meeting of the
Panel is scheduled for Monday, July 16,
2018 from 9:00 a.m. to 5:00 p.m.,
Eastern Daylight Savings Time (E.D.T.)
and Tuesday, July 17, 2018, from 9:00
a.m. to 5:00 p.m., E.D.T. The Panel is
also expected to participate in the 2018
Annual Laboratory Public Meeting on
June 25, 2018 in order to gather
information and ask questions to
presenters if they choose. Notice of the
2018 Annual Laboratory Public Meeting
is published elsewhere in this issue of
the Federal Register.
Webinar, Webcast, and
Teleconference Meeting Information:
The Panel meeting will be conducted
only via webinar, webcast or by
teleconference. The meeting registration
information, teleconference dial-in
instructions, and related webcast and
webinar details will be posted on the
meeting agenda, which will be available
on the CMS website approximately 2
weeks prior to the meeting at https://
www.cms.gov/Regulations-andGuidance/Guidance/FACA/
AdvisoryPanelonClinical
DiagnosticLaboratoryTests.html. A
preliminary agenda is described in
Section II. of this notice.
Meeting Registration: Registration is
required to participate in this public
meeting. Interested participants will be
able to access the registration,
teleconference, webcast, and webinar
instructions, by following the
instructions on the meeting agenda.
There is no deadline for meeting
registration.
FOR FURTHER INFORMATION CONTACT:
Glenn C. McGuirk, Designated Federal
Official (DFO), 410–786–5723, email
CDLTPanel@cms.hhs.gov. Press
inquiries are handled through the CMS
Press Office at (202) 690–6145. For
additional information on the Panel,
please refer to the CMS website at
https://www.cms.gov/Regulations-andGuidance/Guidance/FACA/Advisory
PanelonClinicalDiagnosticLaboratory
Tests.html.
SUPPLEMENTARY INFORMATION:
I. Background
The Advisory Panel on Clinical
Diagnostic Laboratory Tests (the Panel)
is authorized by section 1834A(f)(1) of
the Social Security Act (the Act) (42
U.S.C. 1395m–1), as established by
VerDate Sep<11>2014
18:57 Mar 29, 2018
Jkt 244001
section 216(a) of the Protecting Access
to Medicare Act of 2014 (PAMA) (Pub.
L. 113–93), enacted on April 1, 2014).
The Panel is subject to the Federal
Advisory Committee Act (FACA), as
amended (5 U.S.C. Appendix 2), which
sets forth standards for the formation
and use of advisory panels.
Section 1834A(f)(1) of the Act directs
the Secretary of the Department of
Health and Human Services (the
Secretary) to consult with an expert
outside advisory panel established by
the Secretary, composed of an
appropriate selection of individuals
with expertise in issues related to
clinical diagnostic laboratory tests. Such
individuals may include molecular
pathologists, researchers, and
individuals with expertise in laboratory
science or health economics.
The Panel will provide input and
recommendations to the Secretary and
the Administrator of the Center for
Medicare & Medicaid Services (CMS),
on the following:
• The establishment of payment rates
under section 1834A of the Act for new
clinical diagnostic laboratory tests,
including whether to use
‘‘crosswalking’’ or ‘‘gapfilling’’
processes to determine payment for a
specific new test.
• The factors used in determining
coverage and payment processes for
new clinical diagnostic laboratory tests.
• Other aspects of the new payment
system under section 1834A of the Act.
A notice announcing the
establishment of the Panel and soliciting
nominations for members was
published in the October 27, 2014
Federal Register (79 FR 63919 through
63920). In the August 7, 2015 Federal
Register (80 FR 47491), we announced
membership appointments to the Panel
along with the first public meeting date
for the Panel, which was held on August
26, 2015. Subsequent meetings of the
Panel were also announced in the
Federal Register.
The Panel’s charter provides that
Panel meetings will be held up to 4
times annually and the Panel shall
consist of up to 15 individuals
appointed by the Secretary’s or the CMS
Administrator’s designee to serve a term
of up to 3 years. Members may serve
after the expiration of his or her term
until a successor has been sworn in. A
Panel member selected to replace
another Panel member who has resigned
before the end of his or her term, shall
serve for the balance of the original
Panel member’s term.
A notice requesting nominations to
the Panel was published in the
September 29, 2017 Federal Register (82
FR 45590 through 45592). In that notice,
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
13757
we indicated that nominations would be
accepted on a continuous basis. As a
result of that notice, the Secretary’s
designee approved the appointment of
the following new Panel members:
• Aaron Bossler, M.D., Ph.D.
• Pranil Chandra, D.O.
• Kimberley Hanson, M.D., MHS,
FIDSA
The three new Panel member
appointments are for 3-year terms
beginning July 1, 2018. Current Panel
members include:
• Geoffrey Baird, M.D., Ph.D.
• Vickie Baselski, Ph.D.
• William Clarke, Ph.D., M.B.A.,
DABCC, FACB
• Stanley R. Hamilton, M.D.
• Raju Kucherlapati, Ph.D.
• Bryan A. Loy, M.D., M.B.A.
• Gail Marcus, M.S.E., M.B.A.
• Carl Morrison, M.D., D.V.M.
• Michele M. Schoonmaker, Ph.D.
• Rebecca Sutphen, M.D.
Terms have expired (or will expire
during calendar year 2018) for the
following Panel members:
• Stephen Bauer, M.D.
• Judith Davis, M.S.
• Curtis Hanson, M.D.
• Kandice Kottke-Marchant M.D., Ph.D.
• Victoria Pratt, Ph.D.
II. Agenda
The Agenda for the July 16 and 17,
2018 Panel Meeting will provide for
discussion and comment on the
following topics as designated in the
Panel’s charter:
• CY 2019 Clinical Laboratory Fee
Schedule (CLFS) new and reconsidered
test codes, which will be posted on the
CMS website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/ClinicalLabFeeSched/
Laboratory_Public_Meetings.html.
• Other CY 2019 CLFS issues
designated in the Panel’s charter and
further described on our Agenda.
A detailed Agenda will be posted
approximately 2 weeks before the
meeting, on the CMS website at https://
www.cms.gov/Regulations-andGuidance/Guidance/FACA/
AdvisoryPanelonClinical
DiagnosticLaboratoryTests.html. The
Panel will make recommendations to
the Secretary of the Department of
Health and Services and the
Administrator of CMS regarding
crosswalking and gapfilling for new and
reconsidered laboratory tests discussed
during the 2018 Annual Laboratory
Public Meeting. The Panel will also
provide input on other CY 2019 CLFS
issues that are designated in the Panel’s
charter and specified on the meeting
agenda.
E:\FR\FM\30MRN1.SGM
30MRN1
13758
Federal Register / Vol. 83, No. 62 / Friday, March 30, 2018 / Notices
III. Special Accommodations
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Individuals requiring special
accommodations must include the
request for these services during
registration.
Administration for Children and
Families
Submission for OMB Review;
Comment Request
IV. Meeting Participation
This meeting is open to the public. As
noted previously, the public may
participate in the meeting via
teleconference, webcast, and webinar.
There will not be an in-person meeting
location for this public Panel meeting.
In addition, meeting registration is
required to access the meeting; however,
there is no deadline for registration.
V. Panel Recommendations and
Discussions
The Panel’s recommendations will be
posted approximately 2 weeks after the
meeting on the CMS website at https://
www.cms.gov/Regulations-andGuidance/Guidance/FACA/
AdvisoryPanelonClinicalDiagnostic
LaboratoryTests.html.
VI. Copies of the Charter
The Secretary’s Charter for the
Advisory Panel on Clinical Diagnostic
Laboratory Tests is available on the
CMS website at https://cms.gov/
Regulations-and-Guidance/Guidance/
FACA/AdvisoryPanelonClinical
DiagnosticLaboratoryTests.html or you
may obtain a copy of the charter by
submitting a request to the contact listed
in the FOR FURTHER INFORMATION
CONTACT section of this notice.
VII. Collection of Information
Requirements
This document does not impose
information collection requirements,
that is, reporting, recordkeeping or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
Dated: March 20, 2018.
Seema Verma,
Administrator, Centers for Medicare &
Medicaid Services.
[FR Doc. 2018–06556 Filed 3–29–18; 8:45 am]
BILLING CODE 4120–01–P
Title: Formative Data Collections for
ACF Research and Program Support.
OMB No.: 0970–0356.
Description: The Office of Planning,
Research, and Evaluation (OPRE), in the
Administration for Children and
Families (ACF) at the U.S. Department
of Health and Human Services (HHS)
intends to request approval from the
Office of Management and Budget
(OMB) to renew a generic clearance to
conduct a variety of formative data
collections with more than nine
respondents. The data collections will
inform future research and program
support but will not be highly
systematic nor intended to be
statistically representative.
ACF programs promote the economic
and social well-being of families,
children, individuals and communities.
OPRE studies ACF programs, and the
populations they serve, through rigorous
research and evaluation projects. These
include evaluations of existing
programs, evaluations of innovative
approaches to helping low income
children and families, research
syntheses and descriptive and
exploratory studies. OPRE’s research
serves to provide further understanding
of current programs and service
populations, explore options for
program improvement, and assess
alternative policy and program designs.
OPRE anticipates undertaking a variety
of new research projects related to
welfare, employment and selfsufficiency, Head Start, child care,
healthy marriage and responsible
fatherhood, family and youth services,
home visiting, child welfare, and other
areas of interest to ACF. Many ACF
program offices find a need to learn
more about funded program services to
inform internal decision-making and to
provide adequate support. Some
program offices conduct their own
research and evaluation projects.
Under this generic clearance, ACF
would engage in a variety of formative
data collections with researchers,
practitioners, TA providers, service
providers and program participants
throughout the field to fulfill the
following goals: (1) Inform the
development of ACF research, (2)
maintain a research agenda that is
rigorous and relevant, (3) ensure that
research products are as current and
responsive to audience needs as
possible and (4) inform the provision of
technical assistance. ACF envisions
using a variety of techniques including
semi-structured discussions, focus
groups, and telephone or in-person
interviews, in order to reach these goals.
Following standard OMB
requirements, OPRE will submit a
change request for each individual data
collection activity under this generic
clearance. Each request will include the
individual instrument(s), a justification
specific to the individual information
collection, and any supplementary
documents. OMB should review
requests within 10 days of submission.
Under this generic IC information will
not be collected with the primary
purpose of publication, but findings are
meant to inform ACF activities and may
be incorporated into documents or
presentations that are made public. The
following are some examples of ways in
which we may disseminate information
resulting from these data collections:
Research design documents or reports;
research or technical assistance plans;
background materials for technical
workgroups; concept maps, process
maps, or conceptual frameworks;
contextualization of research findings
from a follow-up data collection that has
full PRA approval; informational reports
to stakeholders such as funders,
grantees, local implementing agencies,
and/or TA providers. In presenting
findings, we will describe the study
methods and limitations with regard to
generalizability and as a basis for policy.
Respondents: Key stakeholder groups
involved in ACF projects and programs,
state or local government officials,
service providers, participants in ACF
programs or similar comparison groups;
experts in fields pertaining to ACF
research and programs, or others
involved in conducting ACF research or
evaluation projects.
amozie on DSK30RV082PROD with NOTICES
ANNUAL BURDEN ESTIMATES
Estimated
total
number of
respondents
Instrument type
Semi-Structured Discussions, Focus Groups ..................................................
Interviews .........................................................................................................
VerDate Sep<11>2014
18:57 Mar 29, 2018
Jkt 244001
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Estimated
number of
responses per
respondent
2,000
1,000
E:\FR\FM\30MRN1.SGM
1
1
30MRN1
Average
burden hours
per response
2
1
Estimated
total burden
hours
4,000
1,000
]]>Agencies
[Federal Register Volume 83, Number 62 (Friday, March 30, 2018)]
[Notices]
[Pages 13756-13758]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-06556]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-1706-N]
Medicare Program; Membership and Meeting Announcement for the
Advisory Panel on Clinical Diagnostic Laboratory Tests
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the appointment of three new members to
the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests
(the Panel) and the next public meeting for the Panel, which is
scheduled on Monday, July 16, 2018 and Tuesday, July 17, 2018.
[[Page 13757]]
The purpose of the Panel is to advise the Secretary of the
Department of Health and Human Services and the Administrator of the
Centers for Medicare & Medicaid Services on issues related to clinical
diagnostic laboratory tests.
DATES:
Meeting Dates: The meeting of the Panel is scheduled for Monday,
July 16, 2018 from 9:00 a.m. to 5:00 p.m., Eastern Daylight Savings
Time (E.D.T.) and Tuesday, July 17, 2018, from 9:00 a.m. to 5:00 p.m.,
E.D.T. The Panel is also expected to participate in the 2018 Annual
Laboratory Public Meeting on June 25, 2018 in order to gather
information and ask questions to presenters if they choose. Notice of
the 2018 Annual Laboratory Public Meeting is published elsewhere in
this issue of the Federal Register.
Webinar, Webcast, and Teleconference Meeting Information: The Panel
meeting will be conducted only via webinar, webcast or by
teleconference. The meeting registration information, teleconference
dial-in instructions, and related webcast and webinar details will be
posted on the meeting agenda, which will be available on the CMS
website approximately 2 weeks prior to the meeting at https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html. A preliminary
agenda is described in Section II. of this notice.
Meeting Registration: Registration is required to participate in
this public meeting. Interested participants will be able to access the
registration, teleconference, webcast, and webinar instructions, by
following the instructions on the meeting agenda. There is no deadline
for meeting registration.
FOR FURTHER INFORMATION CONTACT: Glenn C. McGuirk, Designated Federal
Official (DFO), 410-786-5723, email [email protected]. Press
inquiries are handled through the CMS Press Office at (202) 690-6145.
For additional information on the Panel, please refer to the CMS
website at https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html.
SUPPLEMENTARY INFORMATION:
I. Background
The Advisory Panel on Clinical Diagnostic Laboratory Tests (the
Panel) is authorized by section 1834A(f)(1) of the Social Security Act
(the Act) (42 U.S.C. 1395m-1), as established by section 216(a) of the
Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113-93),
enacted on April 1, 2014). The Panel is subject to the Federal Advisory
Committee Act (FACA), as amended (5 U.S.C. Appendix 2), which sets
forth standards for the formation and use of advisory panels.
Section 1834A(f)(1) of the Act directs the Secretary of the
Department of Health and Human Services (the Secretary) to consult with
an expert outside advisory panel established by the Secretary, composed
of an appropriate selection of individuals with expertise in issues
related to clinical diagnostic laboratory tests. Such individuals may
include molecular pathologists, researchers, and individuals with
expertise in laboratory science or health economics.
The Panel will provide input and recommendations to the Secretary
and the Administrator of the Center for Medicare & Medicaid Services
(CMS), on the following:
The establishment of payment rates under section 1834A of
the Act for new clinical diagnostic laboratory tests, including whether
to use ``crosswalking'' or ``gapfilling'' processes to determine
payment for a specific new test.
The factors used in determining coverage and payment
processes for new clinical diagnostic laboratory tests.
Other aspects of the new payment system under section
1834A of the Act.
A notice announcing the establishment of the Panel and soliciting
nominations for members was published in the October 27, 2014 Federal
Register (79 FR 63919 through 63920). In the August 7, 2015 Federal
Register (80 FR 47491), we announced membership appointments to the
Panel along with the first public meeting date for the Panel, which was
held on August 26, 2015. Subsequent meetings of the Panel were also
announced in the Federal Register.
The Panel's charter provides that Panel meetings will be held up to
4 times annually and the Panel shall consist of up to 15 individuals
appointed by the Secretary's or the CMS Administrator's designee to
serve a term of up to 3 years. Members may serve after the expiration
of his or her term until a successor has been sworn in. A Panel member
selected to replace another Panel member who has resigned before the
end of his or her term, shall serve for the balance of the original
Panel member's term.
A notice requesting nominations to the Panel was published in the
September 29, 2017 Federal Register (82 FR 45590 through 45592). In
that notice, we indicated that nominations would be accepted on a
continuous basis. As a result of that notice, the Secretary's designee
approved the appointment of the following new Panel members:
Aaron Bossler, M.D., Ph.D.
Pranil Chandra, D.O.
Kimberley Hanson, M.D., MHS, FIDSA
The three new Panel member appointments are for 3-year terms
beginning July 1, 2018. Current Panel members include:
Geoffrey Baird, M.D., Ph.D.
Vickie Baselski, Ph.D.
William Clarke, Ph.D., M.B.A., DABCC, FACB
Stanley R. Hamilton, M.D.
Raju Kucherlapati, Ph.D.
Bryan A. Loy, M.D., M.B.A.
Gail Marcus, M.S.E., M.B.A.
Carl Morrison, M.D., D.V.M.
Michele M. Schoonmaker, Ph.D.
Rebecca Sutphen, M.D.
Terms have expired (or will expire during calendar year 2018) for
the following Panel members:
Stephen Bauer, M.D.
Judith Davis, M.S.
Curtis Hanson, M.D.
Kandice Kottke-Marchant M.D., Ph.D.
Victoria Pratt, Ph.D.
II. Agenda
The Agenda for the July 16 and 17, 2018 Panel Meeting will provide
for discussion and comment on the following topics as designated in the
Panel's charter:
CY 2019 Clinical Laboratory Fee Schedule (CLFS) new and
reconsidered test codes, which will be posted on the CMS website at
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Laboratory_Public_Meetings.html.
Other CY 2019 CLFS issues designated in the Panel's
charter and further described on our Agenda.
A detailed Agenda will be posted approximately 2 weeks before the
meeting, on the CMS website at https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html. The Panel will
make recommendations to the Secretary of the Department of Health and
Services and the Administrator of CMS regarding crosswalking and
gapfilling for new and reconsidered laboratory tests discussed during
the 2018 Annual Laboratory Public Meeting. The Panel will also provide
input on other CY 2019 CLFS issues that are designated in the Panel's
charter and specified on the meeting agenda.
[[Page 13758]]
III. Special Accommodations
Individuals requiring special accommodations must include the
request for these services during registration.
IV. Meeting Participation
This meeting is open to the public. As noted previously, the public
may participate in the meeting via teleconference, webcast, and
webinar. There will not be an in-person meeting location for this
public Panel meeting. In addition, meeting registration is required to
access the meeting; however, there is no deadline for registration.
V. Panel Recommendations and Discussions
The Panel's recommendations will be posted approximately 2 weeks
after the meeting on the CMS website at https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html.
VI. Copies of the Charter
The Secretary's Charter for the Advisory Panel on Clinical
Diagnostic Laboratory Tests is available on the CMS website at https://cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html or you may obtain
a copy of the charter by submitting a request to the contact listed in
the FOR FURTHER INFORMATION CONTACT section of this notice.
VII. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting, recordkeeping or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.).
Dated: March 20, 2018.
Seema Verma,
Administrator, Centers for Medicare & Medicaid Services.
[FR Doc. 2018-06556 Filed 3-29-18; 8:45 am]
BILLING CODE 4120-01-P
